Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 9/20 | 0.66 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.59 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | DRD2 | P14416 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | CCR8 | P51685 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6496007 | 0.88 | OPRM1 (0.83) | OPRM1OPRK1OPRL1DRD2DRD4 | |
| SCHEMBL6504966 | 0.78 | OPRM1 (0.70) | OPRM1OPRK1OPRL1DRD2DRD4 | |
| SCHEMBL6504138 | 0.78 | CHRM1 (0.77) | OPRM1OPRK1OPRL1DRD2DRD4 | |
| SCHEMBL6504792 | 0.78 | OPRM1 (0.72) | OPRM1OPRK1OPRL1DRD2DRD4 | |
| SCHEMBL7067624 | 0.77 | OPRM1 (0.74) | OPRM1OPRK1OPRL1DRD2DRD4 | |
| SCHEMBL7068005 | 0.77 | OPRM1 (0.84) | OPRM1OPRK1OPRL1DRD2DRD4 | |
| SCHEMBL6498522 | 0.77 | OPRM1 (0.74) | OPRM1OPRK1OPRL1DRD2DRD4 | |
| SCHEMBL4931452 | 0.77 | OPRM1 (0.59) | OPRM1OPRK1OPRL1POLBDRD2 | |
| SCHEMBL6504972 | 0.77 | OPRM1 (0.68) | OPRM1OPRK1OPRL1DRD2DRD4 | |
| SCHEMBL6504180 | 0.77 | OPRM1 (0.76) | OPRM1OPRK1OPRL1DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. | 2005-06-30 | — | — | US | disclosed |
| WO-2003037271-A2 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREFOR | MILLENNIUM PHARMACEUTICALS,INC. (US) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | CCR8, CCL11, CCR5 | OPRM1 494/4885OPRK1 246/4885OPRL1 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.